RxDoctor Payments Data

Charles Rassier, MD

Ophthalmology · Union, NJNPI 1902025794

Payments from drug & device makers

$3,876in general payments, 2019–2025

Across 218 payments — averaging $17.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Glaukos Corporation$623
  • Sun Pharmaceutical Industries Inc.$531
  • Kala Pharmaceuticals, Inc.$182
  • Tarsus Pharmaceuticals, Inc.$177
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$148
  • plus $1K from 16 others

What the payments were for

  • Food & beverage$3,876100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,876 in reported general payments places this provider in the 75th percentile of 583 ophthalmology providers in New Jersey.

See all ophthalmology providers in New Jersey

Medicare billing

Part B allowed, 2024
$434,993
Medicare patients
665
Services billed
4,264

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost122$69,660
XdemvyLotilaner17$31,978
XiidraLifitegrast23$23,311
CombiganBrimonidine Tartrate/Timolol44$19,908
RestasisCyclosporine17$17,058
Travoprost51$14,980
Prednisolone Acetate287$12,695
SimbrinzaBrinzolamide/Brimonidine Tart25$12,403
Alphagan PBrimonidine Tartrate22$11,556
Timolol Maleate147$11,484
RocklatanNetarsudil Mesylat/Latanoprost25$11,273
Brimonidine Tartrate123$10,891
Cyclosporine17$9,887
Latanoprost459$6,646
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol21$5,262

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Combigan, Restasis, Alphagan P$1,172$118,183205 claims
Tarsus Pharmaceuticals, Inc.Xdemvy$177$31,97817 claims
Bausch & Lomb Americas Inc.Xiidra$27$23,31123 claims
AlconSimbrinza$82$12,40325 claims
Aerie Pharmaceuticals, Inc.Rocklatan$53$11,27325 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate$148$3,48013 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 583 ophthalmology providers in New Jersey.

Other ophthalmology in Union

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →